The proportion of patients with cancer that benefit from precision oncology remains under debate. Suehnholz and colleagues sought to quantify the expansion of clinical actionability over a 5-year period from 2017 to 2022 by annotating 47,271 clinically sequenced solid tumors for actionable molecular alterations using the OncoKB knowledge base and showed that the fraction of tumors harboring a standard care response biomarker increased (8.9% to 31.6%) while tumors carrying non-actionable drivers were reduced (44.2% to 22.8%). Additionally, frequent alterations in TP53, KRAS, and CDKN2A were observed in tumors with limited or no clinical actionability. These results indicate that progress has been made with precision oncology-based treatment paradigms, but strategies to target currently undruggable oncogenic drivers remain an unmet need.

See article, p. 49.

Despite the efficacy of Bruton's tyrosine kinase (BTK) inhibitors in B-cell malignancies, relapse occurs over time and therapeutic options for patients with relapsed/refractory disease...

You do not currently have access to this content.